If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

BAE Systems Contract

16 Nov 2006 07:01

Imperial Innovations Group plc16 November 2006 Imperial Innovations Group plc ("Imperial Innovations") Contract awarded by BAE Systems Imperial Innovations Group plc (AIM: IVO), the technology commercialisation andinvestment company, has been awarded a contract by BAE Systems to commercialiseselected intellectual property (IP) arising from research activities undertakenwithin BAE Systems Advanced Technology Centre (ATC). As part of the agreement, Imperial Innovations will use its expertise to selectpotential opportunities from the research generated by the 400 scientists andengineers who work within the ATC which fall outside of their chosen markets.Imperial Innovations will then apply its wide experience in commercialising thetechnology through either licensing or forming and incubating a company. Under the terms of the contract, Imperial Innovations will receive a share ofthe equity stake of any company it forms or a percentage stake of the royalty itreceives from a licence deal based on BAE Systems' IP. To lead thecommercialisation of their non-core IP, BAE Systems has agreed to fund adedicated relationship manager at Imperial Innovations. The relationship managerwill also source relevant technology and IP opportunities in support of BAESystems core operations from Imperial College London and other sources. Susan Searle, CEO of Imperial Innovations said, "This partnership is a veryexciting opportunity for Imperial Innovations; not only will we have access to apipeline of IP from an organisation as highly-regarded as BAE Systems, but theagreement also emphasises our strategy of building and developing strongrelationships with industry. " James Baker, Director of Advanced Technology Centre, BAE Systems, said, "We lookforward to developing this significant partnership with Imperial Innovations,not only to develop benefits from the commercialisation of technologies withinthe ATC, but also to build on the partnership to identify and access keytechnologies and capabilities from the commercial sector, aligned in support ofthe MOD's Defence Technology Strategy." -End- For more information contact: Imperial Innovations Susan Searle, Chief Executive Officer +44 (0)20 7594 6591Lucy Ahfong, Marketing Communications Executive +44 (0)20 7594 6644 M:Communications Patrick d'Ancona / Eleanor Williamson +44 (0)20 7153 1539 Notes to Editors About Imperial Innovations Imperial Innovations is one of the UK's leading technology transfer andcommercialisation companies. The company was founded in 1986 and its ordinaryshares admitted to trading on the AIM Market of London Stock Exchange plc inJuly 2006, raising £26 million. The company's integrated approach encompassesthe identification of ideas, protection of intellectual property, developmentand licensing of technology and formation, incubation and investment intechnology businesses. A wide range of technologies are commercialised withinthe areas of healthcare, energy, environment and emerging technology trends. Based at Imperial College London, the company has established equity holdings in58 spin-out companies and has completed 90 commercial agreements. ImperialInnovations also commercialises technologies originating from outside ImperialCollege through incubation contracts with the Carbon Trust and WRAP and hasrelationships with a number of multinational corporations. Imperial Innovations has invested in a range of technology businesses includingThe Acrobot Company Limited, Cardiak Limited, deltaDOT Limited, Future Waves PTELimited, HeliSwirl Technologies Limited, InforSense Limited, Lontra Limited,Midaz Lasers Limited, NanoBioDesign Limited, Nexeon Limited, NovaThera Limited,Thiakis Limited and Veryan Medical Limited. Imperial Innovations currently holds shares in four technology businesses nowlisted on AIM including the fuel cell company, Ceres Power plc. Website: www.imperialinnovations.co.uk About BAE SYSTEMS BAE Systems is the premier transatlantic defence and aerospace companydelivering a full range of products and services for air, land and naval forces,as well as advanced electronics, information technology solutions and customersupport services. With 86,000 employees worldwide, BAE Systems' sales exceededGB£15.4 billion (US$28 billion) in 2005. Website: www.baesystems.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th May 20147:00 amRNSVeryan announces results on two-year Mimics study
22nd May 20147:00 amRNSYoyo closes £2.8 million seed investment round
6th May 20142:45 pmRNSHolding(s) in Company
24th Apr 20147:00 amRNSNexeon completes manufacturing facility
14th Apr 201412:00 pmRNSDirector change
3rd Apr 20143:36 pmRNSDirector's share purchase
28th Mar 20147:01 amRNSHalf Yearly Report
13th Mar 20141:04 pmRNSNotice of Results
13th Mar 20147:01 amRNSCircassia announces offer price
26th Feb 20147:40 amRNSCircassia indicative pricing notification
6th Feb 20147:03 amRNSCircassia announces intention to float
28th Jan 20147:00 amRNSAppointment of Joint Broker
7th Jan 20147:00 amRNSCell Medica achieves EU orphan drug designation
30th Dec 201310:00 amRNSFurther investment in TopiVert
18th Dec 20137:00 amRNS£5.1m funding round for Econic Technologies
17th Dec 201312:32 pmRNSResult of AGM
17th Dec 20139:00 amRNS£17.5m funding round for Crescendo Biologics
11th Dec 20137:00 amRNSIXICO launches first CE marked device
10th Dec 20137:00 amRNSSeed funding round for Cambridge spinout Aqdot
6th Dec 20137:00 amRNSGrant of share options
22nd Nov 20133:24 pmRNSOxford Immunotec trading commences on NASDAQ
20th Nov 20139:25 amRNSPulmocide receives £17m Series A funding
18th Nov 20137:00 amRNSMISSION Therapeutics receives £20m funding
16th Oct 20137:01 amRNSOxford Immunotec makes public S1 for potential IPO
16th Oct 20137:00 amRNSBoard Changes
16th Oct 20137:00 amRNSFinal Results
1st Oct 20139:00 amRNSCircassia grass allergy treatment success
26th Sep 20137:00 amRNSCell Medica opens commercial facility in Germany
23rd Sep 20137:05 amRNSIXICO expands into digital healthcare
23rd Sep 20137:00 amRNSProposed acquisition of IXICO Limited
20th Sep 20139:00 amRNSNotice of Results
12th Sep 20137:00 amRNSCircassia phase II clinical study success
10th Sep 20137:00 amRNSLeads £8m funding round in Plaxica
29th Aug 20137:00 amRNSInvestment in new mobile payments business
12th Aug 20136:01 pmRNSDirector/PDMR Shareholding
26th Jul 20138:45 amRNSPortfolio company PolyTherics merges with Antitope
17th Jul 20137:00 amRNSDirectorate Change
2nd Jul 20137:00 amRNS£30m loan from EIB for healthcare investment
25th Jun 20137:00 amRNSInvestment in PsychologyOnline
4th Jun 20137:00 amRNSAutifony starts phase I trial
8th May 20137:00 amRNSCell Medica treats first patient in new trial
29th Apr 20137:00 amRNSInvestment team appointment
17th Apr 20139:26 amRNSBoard change
22nd Mar 20137:00 amRNSHalf year results
1st Mar 20139:22 amRNSNotice of Results
1st Mar 20138:38 amRNSNotification of major interest in shares
25th Feb 20137:00 amRNSCircassia's cat allergy treatment
14th Feb 20137:00 amRNSInvestment in new technology company
23rd Jan 20137:00 amRNS£1.5m investment in new software portfolio company
21st Jan 20133:45 pmRNSListing of shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.